293 related articles for article (PubMed ID: 25297911)
1. Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
McKeage K
Drugs; 2014 Oct; 74(16):1927-1946. PubMed ID: 25297911
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Deeks ED
Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin: in type 2 diabetes mellitus.
Scott LJ
Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
5. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
8. Review of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Setter SM
Clin Ther; 2012 May; 34(5):993-1005. PubMed ID: 22440191
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
Ohmura T; Hayashi N; Encinas J
Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.
Agrawal R; Jain P; Dikshit SN
Curr Drug Targets; 2012 Jun; 13(7):970-83. PubMed ID: 22420306
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin use in older individuals with type 2 diabetes.
Pratley RE
Clin Interv Aging; 2014; 9():1109-14. PubMed ID: 25083132
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin as add-on therapy for type 2 diabetes - an overview.
Brown DX; Choudhury M; Evans M
Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]